January 26, 2018 / 8:35 PM / a month ago

BRIEF-Verastem Presents Preclinical Data Highlighting The Effects Of Duvelisib In Combination With Immune Checkpoint Or Co-Stimulatory Antibodies In B Cell Lymphoma Model

Jan 26 (Reuters) - Verastem Inc:

* VERASTEM PRESENTS PRECLINICAL DATA AT ASCO-SITC HIGHLIGHTING THE SYNERGISTIC EFFECTS OF DUVELISIB IN COMBINATION WITH IMMUNE CHECKPOINT OR CO-STIMULATORY ANTIBODIES IN B CELL LYMPHOMA MODEL

* VERASTEM - DATA SUPPORT EXPLORATION OF DUVELISIB IN COMBINATION WITH ANTI-PD-1/PD-L1 OR CO-STIMULATORY ANTIBODIES IN PATIENTS WITH B CELL MALIGNANCIES

* VERASTEM INC - DUVELISIB IS BEING STUDIED IN OTHER HEMATOLOGIC MALIGNANCIES INCLUDING PERIPHERAL T CELL LYMPHOMA

* VERASTEM INC - PLANS TO SUBMIT NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR DUVELISIB​ DURING Q1 2018

* VERASTEM INC - DUVELISIB ALONE, ANTI-PD-1 ALONE AND ANTI-OX40 ALONE EACH INDUCED TUMOR GROWTH DELAY

* VERASTEM INC - WHEN DUVELISIB AND ANTI-PD-1 WERE COMBINED, STRONG ANTI-TUMOR SYNERGY WAS OBSERVED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below